Unresolved issues in the use of direct acting oral anticoagulants

References

• Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet (London, England). 2020 Nov 28;396(10264):1767–1776
   PubMed Web of Science ®Google Scholar
• Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242–255. doi: 10.1161/CIRCULATIONAHA.121.056355
   PubMed Web of Science ®Google Scholar
• van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014 Sep 18;124(12):1968–1975. doi: 10.1182/blood-2014-04-571232
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, et al. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ: British Med J. 2012;344(jun14 1):e3675. doi: 10.1136/bmj.e3675
   Google Scholar
• Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely Ill medical patients. N Engl J Med. 2016;375(6):534–544. doi: 10.1056/NEJMoa1601747
   PubMed Web of Science ®Google Scholar
• Weitz JI, Wood AJJ. Low-molecular-weight heparins. N Engl J Med. 1997;337(10):688–698. doi: 10.1056/NEJM199709043371007
   PubMed Web of Science ®Google Scholar
• Bauersachs RM. Fondaparinux sodium: recent advances in the management of thrombosis. J Cardiovasc Pharmacol Ther. 2023;28:10742484221145010. doi: 10.1177/10742484221145010
   Web of Science ®Google Scholar
• Warkentin TE, Koster A. Bivalirudin: a review. Expert Opin Pharmacother. 2005 Jul 01;6(8):1349–1371
   PubMed Web of Science ®Google Scholar
• Mohapatra R, Tran M, Gore JM, et al. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era. Am Heart J. 2005 Jul;150(1):19–26. doi: 10.1016/j.ahj.2005.02.012
   PubMed Web of Science ®Google Scholar
• Gurewich V. Ximelagatran–promises and concerns. JAMA. 2005 Feb 9;293(6):736–739.
   PubMed Web of Science ®Google Scholar
• Steffel J, Collins R, Antz M, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European society of cardiology. 2021 Oct 9;23(10):1612–1676. doi: 10.1093/europace/euab065
   Google Scholar
• Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018 Nov;154(5):1121–1201. doi: 10.1016/j.chest.2018.07.040
   PubMed Web of Science ®Google Scholar
• Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and Expert panel report. Chest. 2021;160(6):e545–e608. doi: 10.1016/j.chest.2021.07.055
   PubMed Web of Science ®Google Scholar
• Navar AM, Kolkailah AA, Overton R, et al. Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020. JAHA. 2022 Nov 15;11(22):e026723. doi: 10.1161/JAHA.122.026723
   Google Scholar
• Rymer JA, Chiswell K, Young L, et al. Analysis of oral anticoagulant dosing and adherence to therapy among patients with nonvalvular atrial fibrillation. JAMA Netw Open. 2023;6(6):e2317156–e2317156. doi: 10.1001/jamanetworkopen.2023.17156
   PubMed Web of Science ®Google Scholar
• Dhamane AD, Hernandez I, Di Fusco M, et al. Non-persistence to oral anticoagulation treatment in patients with non-valvular atrial fibrillation in the USA. Am J Cardiovasc Drugs. 2022 May;22(3):333–343. doi: 10.1007/s40256-021-00501-w
   PubMed Web of Science ®Google Scholar
• López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. Bmj(clinical Researched). 2017 Nov 28;359:j5058
   Google Scholar
• Buckley BJR, Lane DA, Calvert P, et al. Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: a systematic review and meta-analysis. J Clin Med. 2022 Jun 30;11(13):3788. doi: 10.3390/jcm11133788
   PubMed Web of Science ®Google Scholar
• Tritschler T, Castellucci LA. It’s time for head-to-head trials with direct oral anticoagulants. Thromb Res. 2019 Aug 01;180:64–69. doi: 10.1016/j.thromres.2019.05.019
   PubMed Web of Science ®Google Scholar
• Kanjee Z, McCann ML, Freed JA. Availability of Specific direct oral anticoagulant reversal agents in US hospitals. JAMA Netw Open. 2021;4(5):e2110079–e2110079. doi: 10.1001/jamanetworkopen.2021.10079
   PubMed Web of Science ®Google Scholar
• Zhang X-L, Zhang X-W, Wang T-Y, et al. Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis. Circulation. 2021;14(12):e007971. doi: 10.1161/CIRCOUTCOMES.121.007971
   PubMed Web of Science ®Google Scholar
• Vries T, Hirsh J, Chan NC. Letter by de Vries et al Regarding article “off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis”. Circulation. 2022;15(5):e008982
   PubMed Web of Science ®Google Scholar
• de Vries TAC, Hirsh J, Xu K, et al. Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?—A systematic review. Thromb Haemost. 2020 Sep;120(9):1323–1329. doi: 10.1055/s-0040-1713889
   PubMedGoogle Scholar
• Chan N, Sager PT, Lawrence J, et al. Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants? Am Heart J. 2018 May;199:59–67.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–1214. doi: 10.1056/NEJMoa1300615
   PubMed Web of Science ®Google Scholar
• Wang TY, Svensson LG, Wen J, et al. Apixaban or warfarin in patients with an on-X mechanical aortic Valve. NEJM Evi. 2023;2(7):EVIDoa2300067. doi: 10.1056/EVIDoa2300067
   Google Scholar
• Andreas M, Moayedifar R, Wieselthaler G, et al. Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device patients. Circ Heart Fail. 2017;10(5):e003709. doi: 10.1161/CIRCHEARTFAILURE.116.003709
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease–associated atrial fibrillation. N Engl J Med. 2022;387(11):978–988. doi: 10.1056/NEJMoa2209051
   PubMed Web of Science ®Google Scholar
• Khairani CD, Bejjani A, Piazza G, et al. Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials. J Am Coll Cardiol. 2023 Jan 3;81(1):16–30. doi: 10.1016/j.jacc.2022.10.008
   PubMed Web of Science ®Google Scholar
• Jaffer IH, Fredenburgh JC, Hirsh J, et al. Medical device-induced thrombosis: what causes it and how can we prevent it? J Thromb Haemost. 2015 Jun;13 Suppl 1:S72–81
   PubMed Web of Science ®Google Scholar
• Jaffer IH, Stafford AR, Fredenburgh JC, et al. Dabigatran is less effective than warfarin at attenuating mechanical heart Valve-induced thrombin generation. JAHA. 2015 Aug 24;4(8):e002322. doi: 10.1161/JAHA.115.002322
   Google Scholar
• Jaffer IH, Fredenburgh JC, Stafford A, et al. Rivaroxaban and dabigatran for suppression of mechanical heart Valve-induced thrombin generation. Ann Thorac Surg. 2020 Aug;110(2):582–590. doi: 10.1016/j.athoracsur.2019.10.091
   PubMed Web of Science ®Google Scholar
• Kunishima S, Hattori M, Kobayashi S, et al. Activation and destruction of platelets in patients with rheumatic heart disease. Eur Heart J. 1994 Mar;15(3):335–338. doi: 10.1093/oxfordjournals.eurheartj.a060499
   PubMed Web of Science ®Google Scholar
• Huang S, Ninivaggi M, Chayoua W, et al. VWF, platelets and the antiphospholipid syndrome. Int J Mol Sci. 2021 Apr 18;22(8):4200. doi: 10.3390/ijms22084200
   PubMed Web of Science ®Google Scholar
• Reitsma SE, Pang J, Raghunathan V, et al. Role of platelets in regulating activated coagulation factor XI activity. Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C365–c374. doi: 10.1152/ajpcell.00056.2020
   PubMed Web of Science ®Google Scholar
• Baird TR, Walsh PN. The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation. J Biol Chem. 2002 Oct 11;277(41):38462–38467
   PubMed Web of Science ®Google Scholar
• Oliver JA, Monroe DM, Roberts HR, et al. Thrombin activates factor XI on activated platelets in the absence of factor XII. Arteriosclerosis Thrombosis Vasc Biol. 1999 Jan;19(1):170–177. doi: 10.1161/01.ATV.19.1.170
   PubMed Web of Science ®Google Scholar
• Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med. 2017;377(5):431–441. doi: 10.1056/NEJMoa1707278
   PubMed Web of Science ®Google Scholar
• Milling TJ, Middeldorp S, Xu L, et al. Final study report of andexanet alfa for major bleeding with factor Xa inhibitors. Circulation. 2023;147(13):1026–1038. doi: 10.1161/CIRCULATIONAHA.121.057844
   PubMed Web of Science ®Google Scholar
• Ansell J, Laulicht BE, Bakhru SH, et al. Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants. Blood. 2021;137(1):115–125. doi: 10.1182/blood.2020007116
   PubMed Web of Science ®Google Scholar
• Levy JH, Ageno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016 Mar;14(3):623–627. doi: 10.1111/jth.13227
   PubMed Web of Science ®Google Scholar
• Reiffel JA, Weitz JI, Reilly P, et al. NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: a cardiac safety research consortium think tank. Am Heart J. 2016 Jul;177:74–86.
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Jan 5;366(1):9–19. doi: 10.1056/NEJMoa1112277
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–1330. doi: 10.1056/NEJMoa1709118
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994–2004. doi: 10.1056/NEJMoa2000052
   PubMed Web of Science ®Google Scholar
• Halton J, Brandão LR, Luciani M, et al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2021 Jan;8(1):e22–e33. doi: 10.1016/S2352-3026(20)30368-9
   PubMed Web of Science ®Google Scholar
• Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020 Jan;7(1):e18–e27. doi: 10.1016/S2352-3026(19)30219-4
   PubMed Web of Science ®Google Scholar
• Weitz JI, Chan NC. Advances in antithrombotic therapy. Arteriosclerosis Thrombosis Vasc Biol. 2019;39(1):7–12. doi: 10.1161/ATVBAHA.118.310960
   PubMed Web of Science ®Google Scholar
• Weitz JI, Chan NC. Novel antithrombotic strategies for treatment of venous thromboembolism. Blood. 2020 Jan 30;135(5):351–359.
   PubMed Web of Science ®Google Scholar
• Chan NC, Weitz JI. Antithrombotic agents. Circ Res. 2019;124(3):426–436. doi: 10.1161/CIRCRESAHA.118.313155
   PubMed Web of Science ®Google Scholar
• Greco A, Laudani C, Spagnolo M, et al. Pharmacology and clinical development of factor XI inhibitors. Circulation. 2023;147(11):897–913. doi: 10.1161/CIRCULATIONAHA.122.062353
   PubMed Web of Science ®Google Scholar
• Nopp S, Kraemmer D, Ay C. Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on Current evidence. Front Cardiovasc Med. 2022;9:903029.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022;399(10333):1383–1390. doi: 10.1016/S0140-6736(22)00456-1
   PubMed Web of Science ®Google Scholar
• Shoamanesh A, Mundl H, Smith EE, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2022;400(10357):997–1007. doi: 10.1016/S0140-6736(22)01588-4
   PubMed Web of Science ®Google Scholar
• Sharma M, Molina CA, Toyoda K, et al. Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. J Stroke Cerebrovasc Dis. 2022 Oct;31(10):106742. doi: 10.1016/j.jstrokecerebrovasdis.2022.106742
   PubMed Web of Science ®Google Scholar
• Milvexian shows potential to reduce the risk of ischaemic stroke: AXIOMATIC-SSP trial presented in a hot line session today at ESC congress 2022 [Internet]. European Society of Cardiology; 2022. Available from: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Milvexian-shows-potential-to-reduce-the-risk-of-ischaemic-stroke
   Google Scholar
• Rao SV, Kirsch B, Bhatt DL, et al. A multicenter, phase 2, randomized, placebo-controlled, Double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation. 2022;146(16):1196–1206. doi: 10.1161/CIRCULATIONAHA.122.061612
   PubMed Web of Science ®Google Scholar